India has just announced a booster vaccine. Why a booster? A delayed interval with a booster generates long-lived plasma and memory cells. To realize durable immunity, a gap of 6 months is ideal. This will also aid in mitigating the threat from Omicron

COVAXIN pediatric results: •Overall found to be safe •Neutralizing antibodies 1.7 fold higher than adults •No serious adverse events •No cases of myocarditis/blood clots, albeit in small numbers •Largest pediatric vaccination drive to commence on Jan 3rd, 2022

#bharatbiotech #covaxin #covid #covid19vacccine #immunization #vaccination #childrensafety #clinicaltrials #vaccinatedandhappy

A new important study: Coronavirus loses 90% of its ability to infect us within 5 minutes of becoming airborne, the world’s first simulations of how the virus survives in exhaled air suggest. 1/

Yes, we can stop getting jabbed 💉 ! 3️⃣drops in each nostril should do. The world's 1️⃣ intranasal Covid-19 vaccine (2-dose): INCOVACC! Kudos to my former colleagues at Bharat Biotech. I am fortunate to be a part of their success.

The 1st results for the Bharat Biotech nasal vaccine (BBV154, approved in India) randomized trial vs shots now posted, superior antibody and cellular immune response (vs ancestral and Omicron); 4-fold less side effects papers.ssrn.com/sol3/papers.cf…

My last #MBA class Harvard Business School 500 cases spread across 4 Semesters! What a journey!

I returned to HBS as a guest lecturer and case protagonist to share the incredible journey of Bharat Biotech during the COVID-19 pandemic. The case is a part of Professor Tadikonda's "Entrepreneurship in the Life Sciences" course, taught to second-year MBA students🙏

The surge in respiratory disease in China, no reason to panic: ⬆️incidence of RSV/Flu/adenovirus in winter 1️⃣’St winter after the stringent COVID-19 lockdown, people may be more susceptible ⬆️ amount of multidrug-resistant M. pneumonia 🚫cant afford complacency 🙏for the 👪

Last week in Hyderabad, we had the privilege of updating Mr. Bill Gates, on our market access strategies for Malaria & Cholera vaccines. Our partnership with the Gates Foundation dates back to 2001, which led to 2 innovative vaccines for Rotavirus and Typhoid #endmalaria

My views on how HMPV vaccine development strategies do not 🙅 necessitate a rapid response model - featured on the Economic Times-Morning Brief Podcast. 🎧 ⬇️ m.economictimes.com/morning-brief-…

🧬Thrilled to share my interview with moneycontrol.com on our next chapter—bringing cell & gene therapy 🔹 Leveraging our virus/GMP-production expertise to slash the cost of CGT platforms 🔹 Same mission, new frontier: equity, innovation 🔗 lnkd.in/gfG5k9hM